RG-101 / Novartis - LARVOL DELTA

Regulus to present updated data supporting RG-101 as novel microRNA therapeutic for the treatment of HCV at The Liver Meeting 2015 (AASLD) (PRNewswire) - "Regulus Therapeutics...announced today that two abstracts related to RG-101...for the treatment of chronic Hepatitis C Virus (HCV) infection, were accepted for presentation at The Liver Meeting...will present extended follow-up data from the Phase I clinical study of RG-101...data examining immunological changes observed in the plasma of patients who received a subcutaneous administration of RG-101 in the completed Phase I study...'we look forward to reporting interim data [Phase II study] by the end of the year.'"

Anticipated conference • Anticipated P1 data • Anticipated P2 data • Hepatitis C Virus

"Nice list of upcoming catalysts$events next few months please add to it $LXRX $TSRO $GBT $ABUS $KPTI $NVAX $BLUE" - ‏@tgtxdough

Anticipated conference • Anticipated P2 data • Hepatitis C Virus

Regulus reports positive top-line data (Regulus Therapeutics Press Release) - P2, N=79; "Regulus... today announced  top-line results from the primary endpoint analysis of one of the company's ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection...RG-101 plus Harvoni continues to demonstrate 100% response rates...results reported today include four new relapses: two in the Olysio arm (weeks 20 and 32) and two in the Daklinza arm (weeks 12 and 24). RG-101 in combination with four weeks of oral DAA therapy has been generally well tolerated with the majority of adverse events considered mild or moderate, and with no study discontinuations."

P2 data • Hepatitis C Virus

Regulus therapeutics shares gain 110% amid positive hepatitis C study (Benzinga) - "Regulus...rallied to $18.33 in pre-market trading, almost tripling in value from Tuesday's $6.77 close. The catalyst for the rally being the announcement of a positive RG-101 study for the treatment of Hepatitis C."

Stock price